For research use only. Not for therapeutic Use.
Omecamtiv mecarbil (CAT: I005262) is a selective cardiac myosin activator that enhances the contractility of the heart muscle. It works by binding to the cardiac myosin protein and increasing its interaction with actin, resulting in increased force generation and improved cardiac function. Omecamtiv mecarbil has been investigated as a potential treatment for heart failure, aiming to improve cardiac performance and alleviate symptoms in patients with reduced ejection fraction. Clinical studies have shown promising results, demonstrating its ability to increase cardiac output and improve exercise capacity in heart failure patients. It represents a novel therapeutic approach for the management of heart failure and is currently being evaluated for its efficacy and safety in ongoing clinical trials.
| Catalog Number | I005262 |
| CAS Number | 873697-71-3 |
| Synonyms | methyl 4-[[2-fluoro-3-[(6-methylpyridin-3-yl)carbamoylamino]phenyl]methyl]piperazine-1-carboxylate |
| Molecular Formula | C20H24FN5O3 |
| Purity | ≥95% |
| Target | Myosin |
| Solubility | DMSO ≥78mg/mL Water <1.2mg/mL Ethanol ≥12mg/mL |
| Storage | 3 years -20C powder |
| Overview of Clinical Research | <span style=”font-size:12px;”><span style=”font-family:arial,helvetica,sans-serif;”>Omecamtiv mecarbil is a cardiac myosin stimulant. </span></span> |
| IC50 | 0.6 uM (EC50) |
| IUPAC Name | methyl 4-[[2-fluoro-3-[(6-methylpyridin-3-yl)carbamoylamino]phenyl]methyl]piperazine-1-carboxylate |
| InChI | InChI=1S/C20H24FN5O3/c1-14-6-7-16(12-22-14)23-19(27)24-17-5-3-4-15(18(17)21)13-25-8-10-26(11-9-25)20(28)29-2/h3-7,12H,8-11,13H2,1-2H3,(H2,23,24,27) |
| InChIKey | RFUBTTPMWSKEIW-UHFFFAOYSA-N |
| SMILES | COC(N1CCN(CC2=CC=CC(NC(NC3=CC=C(C)N=C3)=O)=C2F)CC1)=O |
| Reference | <br /> |
